Latest Intellectual Property News

Page 3 of 89
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Wide Open Agriculture has completed the major physical steps in exiting its German manufacturing facility and is now testing four prospective Asian production partners. The transition could lower fixed costs, but commercial supply still depends on technical trials, partner selection and a definitive agreement.
Victor Sage
Victor Sage
30 Oct 2026
Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.
Victor Sage
Victor Sage
30 Oct 2026
Vection Technologies has started FY27 with stronger customer receipts, a sharply narrower operating cash loss and A$7.0 million in quarter-end cash. The next test is whether Defence, Retelit and URBANnext commitments convert into reported revenue through the year.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
TALi Digital closed its September quarter with $3.9 million in cash after completing a $3.3 million capital raise and winning shareholder approval for the Datasphere transaction. The company has also exercised an option to negotiate exclusive worldwide rights to Technion in-memory computing technology, although the licence remains unsigned and the technology unproven at commercial scale.
Victor Sage
Victor Sage
30 Oct 2026
Basin Energy’s Newmans rare earth discovery has expanded from 3.3 km to 6.7 km, with drilling producing the project’s strongest magnet rare earth results to date. The technical momentum comes with a sharper funding question, as cash stood at A$776,000 and covered an estimated 1.53 quarters of current outgoings.
Victor Sage
Victor Sage
30 Oct 2026
Holista Colltech reported positive adjusted operating cash flow of A$318,000 for the September quarter, although statutory cash flow remained negative after its final ProImmune settlement payment. The company also pushed the planned start of its Collie collagen plant from December 2026 to May-July 2027, while ending the quarter with just A$23,000 in cash.
Victor Sage
Victor Sage
30 Oct 2026
Battery Age Minerals advanced its Bleiberg germanium permits and expanded Falcon Lake to about 60 km², but its cash position now covers an estimated 1.34 quarters of funding. Initial Apex fieldwork also failed to confirm the remote-sensing anomalies that had defined the Utah targets.
Victor Sage
Victor Sage
30 Oct 2026
Beonic has launched its in-house Vision platform across four countries while delivering a profitable first quarter, with EBITDA of A$853,000 and an 83.0% gross margin. The stronger operating result came alongside weaker total revenue, negative operating cash flow and only 1.7 quarters of estimated funding.
Sophie Babbage
Sophie Babbage
29 Oct 2026

Browse the archive

Full archive